iRhythm Technologies (IRTC) Stock Price, News & Analysis

Company Overview

iRhythm Technologies, Inc. is a medical technology company specializing in cardiac arrhythmia diagnostics through proprietary wearable biosensor devices and cloud-based analytics. Its flagship offering, the Zio patch, is a single-use adhesive patch designed to continuously monitor heart rhythm for up to 14 days. Data collected by the device is transmitted to a secure cloud platform where advanced algorithms analyze the recordings to detect irregular heartbeats and generate detailed reports for clinicians.

In addition to the Zio patch, iRhythm provides physician-supported diagnostic services that combine automated signal processing with expert human review. Reports identify occurrences of atrial fibrillation, bradycardia, pauses, tachycardia and other arrhythmic events, helping physicians make informed decisions on patient management. The company partners with hospitals, outpatient centers and physician practices, as well as payers, to support remote cardiac monitoring and streamlined reporting workflows.

Founded in 2006 and headquartered in San Francisco, California, iRhythm initially commercialized its Zio service following FDA clearance in 2011. Since then, the company has expanded its footprint beyond the United States into select markets across Europe and the Asia-Pacific region. Under the leadership of CEO Kevin King and a management team with expertise in cardiovascular diagnostics and digital health, iRhythm continues to invest in research collaborations and product enhancements aimed at improving arrhythmia detection and broadening access to remote cardiac monitoring solutions.

Key Stats

• Today's Range: $135.72 to $138.41
• 50-Day Range: $132.88 to $154.71
• 52-Week Range: $55.92 to $157.13
• Volume: 433,891 shs
• Average Volume: 491,474 shs
• Market Capitalization: $4.35 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $137.30
• Consensus Rating: Moderate Buy

iRhythm Technologies Stock Analysis - MarketRank™

iRhythm Technologies scored higher than 23% of companies evaluated by MarketBeat, and ranked 838th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

iRhythm Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

iRhythm Technologies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for iRhythm Technologies are expected to grow in the coming year, from ($1.98) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iRhythm Technologies is -43.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iRhythm Technologies is -43.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iRhythm Technologies has a P/B Ratio of 46.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.36% of the float of iRhythm Technologies has been sold short.

Short Interest Ratio / Days to Cover

iRhythm Technologies has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in iRhythm Technologies has recently increased by 2.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iRhythm Technologies does not currently pay a dividend.

Dividend Growth

iRhythm Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.36% of the float of iRhythm Technologies has been sold short.

Short Interest Ratio / Days to Cover

iRhythm Technologies has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in iRhythm Technologies has recently increased by 2.33%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.83

News Sentiment

iRhythm Technologies has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for iRhythm Technologies this week, compared to 7 articles on an average week.

Search Interest

2 people have searched for IRTC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, iRhythm Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $796,882.00 in company stock.

Percentage Held by Insiders

Only 1.10% of the stock of iRhythm Technologies is held by insiders.

IRTC Stock Analysis - Frequently Asked Questions

How have IRTC shares performed this year?

iRhythm Technologies' stock was trading at $90.17 at the beginning of 2025. Since then, IRTC shares have increased by 51.1% and is now trading at $136.24.

How were iRhythm Technologies' earnings last quarter?

iRhythm Technologies (NASDAQ:IRTC) released its earnings results on Thursday, May, 1st. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.06. The firm's revenue was up 20.3% compared to the same quarter last year.
Read the conference call transcript.

When did iRhythm Technologies IPO?

iRhythm Technologies (IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are iRhythm Technologies' major shareholders?

iRhythm Technologies' top institutional investors include Banque Pictet & Cie SA (0.10%), Harbor Capital Advisors Inc. (0.09%), Atle Fund Management AB (0.08%) and Truist Financial Corp (0.03%). Insiders that own company stock include Quentin S Blackford, Mark J Day, Chad Patterson, Minang Turakhia, Daniel G Wilson, Patrick Michael Murphy, Douglas Devine, Brice Bobzien, Sumi Shrishrimal, Abhijit Y Talwalkar, Mervin Smith, Marc W Rosenbaum and Merz Cathleen Noel Bairey.
View institutional ownership trends.

How do I buy shares of iRhythm Technologies?

Shares of IRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iRhythm Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iRhythm Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:IRTC
• CIK: 1388658
• Web: www.irhythmtech.com
• Phone: (415) 632-5700
• Fax: N/A
• Employees: 2,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for iRhythm Technologies: $137.30
• High Price Target: $167.00
• Low Price Target: $100.00
• Potential Upside/Downside: -0.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.29 million
• Net Margins: -15.90%
• Pretax Margin: -15.70%
• Return on Equity: -101.04%
• Return on Assets: -9.55%

Debt

• Debt-to-Equity Ratio: 7.47
• Current Ratio: 5.71
• Quick Ratio: 5.58

Sales & Book Value

• Annual Sales: $591.84 million
• Price / Sales: 7.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.90 per share
• Price / Book: 47.48

Miscellaneous

• Outstanding Shares: 31,920,000
• Free Float: 31,574,000
• Market Cap: $4.40 billion
• Optionable: Optionable
• Beta: 1.41